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Purpose: Although many studies have demonstrated im-
provements in short-and long-term outcomes of gastric cancer 
surgery, changes in long-term survival over time are not well- 
established. This study was conducted to evaluate changes in 
host, tumor, and treatment factors in patients treated at a single 
institution over a period of 45-yr. Patients and Methods: We 
retrospectively evaluated 9282 patients with gastric cancer 
from 1955 to 1999, and divided the 45-yr into 4 time frames 
based on published articles: 1955 to 1962 (n = 228), 1963 to 
1972 (n = 891), 1973 to 1988 (n = 2789), and 1989 to 1999 
(n = 5374). Results: Remarkable changes were noted in host, 
tumor, treatment factors, and prognosis. Among host factors, 
patients of more advanced age were identified in the 4th peri-
od and mean age shifted from 49 to 55 yrs. Among tumor fac-
tors, early gastric cancers and upper body tumors increased up 
to 32% and from 7% to 13%, respectively. An increase in the 
annual number of patients (from 29 to 649), gastrectomies 
(from 14 to 600), rate of resection (from 50% to 90%), rate 
of curative resection (up to 92%), and proportion of total gas-
trectomy (from 8% to 29%) was noted. Operative mortality was 
reduced from 6.1% to 0.7%. The overall 5-yr survival rate sig-
nificantly increased from 22% to 65%. Conclusion: Treatment 
results of gastric cancer surgery have improved remarkably 
over the 45-year period. Increase of early stage gastric cancer 
with early diagnosis considerably influenced the improved sur-
vival of patients with gastric cancer. 
Key Words: Gastric cancer, surgery, treatment results 
 
INTRODUCTION
Although the results of gastric cancer treatment 
have considerably improved with improved pro-
gnosis due to early diagnosis, radical operation, 
and the development of adjuvant therapy, patients 
with gastric cancer still have poor prognosis.1,2 
During the past 5 decades, progress in oncology, 
treatment modality and strategy for gastric cancer 
patients has been noted. Recently, treatment 
methods, especially surgical approaches, have 
been tailored to patient and tumor characteristics.3 
At our institute, standardization of surgical 
treatment for gastric cancer, i.e. en bloc extended 
regional lymph node dissection, was first achieved 
in 1983. Since then, we adopted the surgical 
treatment policy of D2 resection for early gastric 
cancer (EGC) and D2 or more extended resection 
for advanced gastric cancer (AGC).4 For patients 
with advanced gastric cancers, adjuvant chemo-
therapy has usually been used, and neoadjuvant 
chemotherapy is used on some patients with 
locally advanced cancers. Nowadays, various 
surgical approaches are being practiced, including 
conventional surgery, function preserving surgery, 
and minimally invasive surgery such as 
laparoscopic surgery and less extensive lymph 
node dissesction. 
This study was conducted to evaluate changes 
of host, tumor, and treatment factors in patients 
treated at a single institution over a 45-yr period 
and their effect on prognosis in a high prevalence 
area.
PATIENTS AND METHODS
We evaluated the clinicopathologic features and 
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Table 1. Comparisons of Host Factors
 ’55 - ’62 ’63 - ’72 ’73 - ’88 ’89 - ’99 p value
Age (Mean, yrs) 49 50 54 55 NA










prognosis of 9282 patients with gastric cancer who 
received surgical intervention from 1955 to 1999. 
Because medical records from 1955 to 1985 were 
not available, the clinicopathologic features of 
patients with gastric cancer treated between 1955 
and 1986 were obtained from the earlier publica-
tions of the institution. Two articles published in 
1964 evaluated 228 patients who underwent 
surgical intervention out of 401 total patients 
admitted for gastric cancer.5,6 Two articles 
published in 1975 and in 1991 included 891 and 
2789 patients, respectively.4,7,8 Medical records of 
5374 patients with gastric cancer treated from 1987 
to 1999 were reviewed. Fortunately, there was no 
overlap in study period among the previous 
papers allowing us to divide the 45-yr interval 
into 4 periods: 1955 to 1962 as the 1st period (n 
= 228); 1963 to 1972 as the 2nd period (n = 891); 
1973 to 1988 as the 3rd period (n = 2789); and 1989 
to 1999 as the 4th period (n = 5374). In the 3rd 
period, tumor node metastasis (TNM) stages were 
classified according to the American Joint 
Committee for Cancer Staging and End Result 
Reporting which was published in 1977.9 For 
survival comparison at each TNM stage, TNM 
staging of the 4th period was also based on the 
same TNM staging system published in 1977.
Statistical analysis
All statistical analyses were performed using 
Statistical Package for Social Science (SPSS) 
version 11.0 for Windows (SPSS, Inc, Chicago, IL, 
USA). Inter-group comparisons of clinicopatholo-
gical variables were made using the Student's 
t-test for continuous variables and 2-tailed 2 test 
for discrete variables. 
Follow up of patients in the 4th period was 
completed until death or the incised date of June 
30, 2004. At the time of the last follow up, 214 
patients (4.4%) had been lost. The median follow- 
up interval for patients alive at the incised date 
was 70 mo (range, 55 - 189 mo). Postoperative 
mortalities, defined as mortalities occurring 
within 30 days after operation, occurred in 34 
cases (0.7%). 
Lost and operative mortality cases were treated 
as censored data for the analysis of survival rates. 
Kaplan-Meier method was used for calculating 
survival rate and difference between the curves 
was assessed using log-rank test.10 The accepted 
level of significance was p < 0.05.
RESULTS
Host & tumor factors
Changes of host and tumor factors are shown 
in Tables 1 and 2. Although exact statistical 
analysis was impossible due to lack of exact 
demographic data in the 1st and 2nd period, 
among host factors, patients of more advanced 
age were identified in the 4th period and the 
mean age was shifted from 49 in the 1st period 
to 55 in the 4th period. There was also a change 
in male to female ratio from 3 : 1 to 2 : 1. Among 
tumor factors, upper body tumors increased from 
7% to 13%. Tumors with differentiated histology 
increased from 36.3% to 39.8% although the 
histologic types were available for the last 2 
periods only. Serosa negative or node negative 
cancers were found more frequently in the later 
periods and early gastric cancers increased up to 
32.6%, thus tumors treated in the later periods 
were found at earlier stages. 
Treatment factors & prognosis
Fig. 1 shows annual number of gastrectomies 
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Table 2. Comparisons of Tumor Factors
’55 - ’62 ’63 - ’72 ’73 - ’88 ’89 - ’99 p value
Analyzed patients (n)     228    568    2,789    4,819
Location < 0.001
Lower 1/3 157 (69.5%) 466 (82.0%) 1,732 (62.1%) 2,249 (46.7%)
Middle 1/3  50 (22.1%)  61 (10.7%)  644 (23.1%) 1,888 (39.2%)
Upper 1/3 15 (6.6%) 30 (5.3%) 252 (9.0%)  601 (12.5%)
Whole  4 (1.8%) 11 (1.9%) 161 (5.8%)  81 (1.7%)
Unknown       2 - - -
Histology < 0.001
Differentiated - -  901 (36.3%) 1,919 (39.8%)
Undifferentiated - - 1,579 (63.7%) 2,900 (60.2%)
Unknown - -  109 -
Depth of invasion < 0.001
Serosa (-)  25 (21.9%)  94 (28.3%)  779 (27.7%) 2,519 (59.1%)
Serosa (+)  89 (78.1%) 238 (71.7%) 1,884 (72.3%) 2,300 (40.9%)
Unknown     114    232  126 -
Nodal involvement < 0.001
Negative  32 (27.9%) 189 (32.2%) 1,260 (47.3%) 2,293 (46.0%)    
Positive  82 (72.1%) 379 (67.8%) 1,403 (52.7%) 2,526 (54.0%) 
Unknown 114    126 - -
Stage   
I - -  392 (14.6%) 1,385 (28.7%)
II - -  677 (25.2%)  863 (17.9%)
III - - 1,321 (49.2%) 2,182 (45.3%)
IV - -  293 (10.9%) 389 (8.1%)
Unknown - - 106 -
performed for gastric cancer, which increased 
gradually over the past 45-yr. After 1990, more 
than 300 cases of gastrectomies were performed 
and more than 500 gastrectomies have been 
performed since 1997. Along with the increase in 
the number of gastrectomies, overall resection and 
curative resection rate were markedly increased 
during the last 2 periods. Most recently, the 
overall resection rate was 89.7% and the curative 
resection rate was 91.9%. The mortality rate of 
resected cases in the 1st period was 6.1% whereas 
it was 0.7% in the 4th period. The follow-up rate 
for each period was also increased, reaching 95.6% 
in the 4th period. Although statistical comparison 
among the periods for survival rates was limited 
due to a lack of available data in the 3 periods, 
5-yr survival rates increased gradually from 22.2% 
to 64.5%. Survival after curative resection in the 
4th period was 70.2% whereas those in the 3rd 
period were 12.4% for 1973 to 1982 and 30.4% for 
1983 to 1988. Relatively accurate stage-by-stage 
comparison could be performed between the 3rd 
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Table 3. Comparisons of Treatment Factors
’55 - ’62 ’63 - ’72 ’73 - ’88 ’89 - ’99 p value
Operated patients (n) 228 891 2,789 5,374 -
Resected patients (n) 114 (50.0%) 568 (55.9%) 2,085 (74.8%)  4,819 (89.7%)  < 0.001
Curative resection - - 1,769 (84.8%) 4,430 (91.9%)
Noncurative resection - -  316 (15.2%) 389 (8.1%)
Type of resection  
Subtotal 103 (90.4%) 534 (94.0%) 1,608 (77.1%) 3,416 (70.9%)
Total 11 (9.6%) 34 (6.0%)  477 (22.9%)  1,403 (29.1%)
Bypass surgery  85 (37.3%) 206 (32.0%)  464 (16.6%) 289 (5.4%) -
Exploration only  29 (12.7%) 117 (13.1%) 240 (8.6%) 266 (4.9%) -
Mortality after gastrectomy  7 (6.1%) - -  34 (0.7%) < 0.001
Table 4. Comparisons of Prognosis and Follow-Up Rates
’55 - ’62 ’63 - ’72 ’73 - ’88 ’89 - ’99 p value
Analyzed patients (n) 228 891 2,789 5,374 -
Follow-up rate (%) 56.1 63.4 76.6 95.6 < 0.001
Overall 5-yr survival (%) 22.2 23.5 22.6 64.5 -
5-yr survival after 






5-yr survival by stage (%)  -
I - - 91.6 94.2
II - - 71.2 73.4
III - - 19.8 44.7
IV - -  0.7 11.1
Fig. 1 Annual number of gastrectomies for gastric cancer 
from 1955 to 1999. 
and 4th periods. Survival differences were noted 
in stages I, II, III, and IV between the 2 periods 
(Table 4).
DISCUSSION
The main findings of the present study are an 
increased proportion of patients with early gastric 
cancer, increased incidence of total gastrectomy 
along with an increase of proximal lesions, and 
decreased mortality related to gastrectomy. In 
conjunction with these changes, the prognosis of 
patients with gastric cancer has improved. 
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In the present study, major changes were 
observed with respect to tumor factors. The 
changes of tumor factors during the last 45 yrs 
originated mainly from early detection. In the 
later years, the earlier stage gastric cancers were 
increased. As the incidence of early gastric cancer 
increased, node negative cancers were also 
increased. These changes appear to have con-
tributed to the recent improved prognosis.
Depth of tumor invasion, lymph node involve-
ment and distant metastasis are important 
prognostic factors according to the UICC/AJCC 
staging system of gastric cancer.11 Surgery is the 
only treatment modality offering hope for cure, 
nevertheless, most patients die from locoregional 
recurrence or distant metastasis even after 
curative surgery for advanced stage cancers.12 
Although the incidence of early gastric cancer is 
increasing, most of the patients are still diagnosed 
at an advanced stage. Therefore, every attempt 
should be made to increase early diagnosis. 
In this study, we found that the proportion of 
patients with early gastric cancer is increased up 
to 32.7% in the 4th period. Currently, gastric 
cancer in Korea is of the most prevalent cancers, 
making endoscopic or radiologic examinations 
more common. Awareness among Koreans has 
also increased, similar to colorectal or prostate 
cancer in Western countries.13,14
Along with the occurrence of more proximal 
tumor lesions, the proportion of total gastrectomies 
has increased. It has been reported that prevalence 
of morbidity and mortality is higher in total 
gastrectomy compared to subtotal gastrectomy.15 
The prognosis of the proximal cancer has been 
reported to be poor for various reasons.16-18 
Increasing numbers of total gastrectomy and the 
complicated biologic features of proximal gastric 
cancers, especially esophagogastric junction cancers, 
require more sophisticated treatment strategies. 
The suggestions of Siewert et al., to classify the 
proximal gastric cancers into 3 types according to 
location and provide different operative options 
based on their classification may be a reliable 
treatment strategy for proximal cancers.19,20
Another important change observed was 
decreased prevalence of operative mortality. 
Although the surgical extent of recent years was 
more extensive than before, shown by increased 
proportion of total gastrectomies, postoperative 
mortality in the 4th period was decreased to 0.7%. 
This reflects the progress made in surgery and 
especially in anesthesia, resulting in improvement 
of peri- and post-operative management. In 
addition to technical advances, specialization in 
gastric cancer treatment at our hospital might 
have also influenced the lower mortality rate, as 
noted in other major surgery areas, such as 
abdominal aortic aneurysm, breast cancer, and 
colorectal cancer.21-25
The present study confirmed previous reports 
that the prognoses of gastric cancer are 
improving.26-30 Overall survival rate of patients 
has gradually been improved from 22.5% to 
64.5%. Survival after curative resection in the 4th 
period was 70.2%, however, in the 3rd period, it 
was 12.4% from 1973 to 1982 and 30.4% from 1983 
to 1988. The survival improvement resulted 
mainly from a host factor, i.e. increases of early 
stage patients, and was reflected in the increase of 
curative resection rates. Advances in treatment 
factors also contributed to improved survival. 
Comparison of survival rates among stages 
showed higher survival in the 4th period than in 
the 3rd period. There exists the possibility of the 
stage migration effect after adopting the 
systematic lymph node dissection. However, the 
survival difference in stages II and III might be 
due to recent advances in surgical treatment, 
including systematic lymph node dissection and 
postoperative adjuvant chemotherapy. In the 
present study. the survival benefit of node 
negative patients (stages I & II) was evident, 
which could exclude the stage migration effect.31,32 
Furthermore, with a better follow-up rate in the 
last 2 periods, comparison of the prognosis in this 
study should be much more reliable.
A major problem of this study was that records 
were reviewed for only cases from 1987 to 1999. 
Data from previous time points were obtained 
from previously published articles, and, no 
statistical analysis could be performed on some of 
the outcome measures. Although this study 
analyzed limited data from a single center 
experience in a retrospective way, we found 
improved outcomes of gastric cancer surgery and 
improved survival of the gastric cancer patients. 
We found that the accumulation of treatment 
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experience with gastric cancer and becoming a 
large volume hospital had an impact on the 
improved treatment outcome of gastric cancer 
patients, but there have been no standardized 
treatment protocols for each period even though 
surgery has been relatively standardized. 
Early diagnosis and radical surgery with 
multimodality adjuvant therapy have markedly 
improved the survival of patients with gastric 
cancer. Nowadays, various surgical approaches, 
such as conventional surgery, function preserving 
surgery, and minimally invasive surgery, are being 
practiced.3 Gastric cancer should be considered as 
a malignancy that requires a multidisciplinary 
approach by a specialized team. Evaluation of the 
effect of a highly developed treatment strategy in 
prospective clinical trial settings is still needed to 
confirm these observations.
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